# OnCo record tikva-allocell (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/tikva-allocell/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "tikva-allocell" ;
  schema:name "Tikva Allocell"@en ;
  schema:description "Tikva Allocell builds ready-made CAR-T cells from healthy donors' T cells that already fight the common Epstein-Barr virus, with an added shield to stop the patient's immune system rejecting them. Its first product targets a protein found on many solid tumours and was preparing for its first trial in 2026."@en ;
  schema:url <https://onco.cc/companies/tikva-allocell/>, <https://www.tikvaallocell.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.tikvaallocell.com/>, <https://tikvaallocell.com/tikva-allocell-secures-8-million-series-a-financing-to-advance-engineered-off-the-shelf-cell-therapies-for-solid-tumors/> ;
  schema:addressCountry "SG" ;
  onco:sections <https://onco.cc/fronts/cell-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/allogeneic-cell-therapy/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/virus-specific-t-cells/> ;
  onco:targets <https://onco.cc/targets/b7h3/> .